Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Engaging with SBIR Topic Q&A During the pre-release period, proposers can directly contact Topic Points of Contact (TPOCs) or submit questions via the Topic Q&A page on DSIP
WADA Prohibition The World Anti-Doping Agency classification for these peptides: GLP3 likely classified under prohibited substances as a GLP-1 receptor agonist Cagrilintide status as amylin analog may fall under peptide hormone prohibitions Combined formulation would be prohibited under multiple substance categories No Therapeutic Use Exemptions (TUEs) available for either component Detection methods under development for anti-doping testing WADAs position reflects that these remain investigational agents without regulatory approval from health authorities worldwide
Thank you for the helpful tutorial video
Cost remains a major barrier, with monthly prices often exceeding $1,000 without insurance coverage
